Results 161 to 170 of about 3,371 (214)

Cariprazine

Nervenheilkunde, 2020
Abstract Objective Cariprazine is a new antipsychotic drug approved for the treatment of schizophrenia in Europe in 2017. Clinical studies suggest advantages of cariprazine in comparison to other antipsychotic agents regarding therapeutic effects on “negative symptoms”, antipsychotic-induced weight gain and increased serum prolactin levels ...
Maximilian Gahr, Simon Riedesser
openaire   +1 more source

Cariprazine (Vraylar)

Canadian Journal of Health Technologies, 2022
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments ...
openaire   +1 more source

Cariprazine modulates sleep architecture in rats

Journal of Psychopharmacology, 2021
Background: Cariprazine is a dopamine D3-preferring D3/D2 receptor partial agonist compound recently introduced to treat schizophrenia and bipolar disorder. Although cariprazine is clinically classified as a low-somnolence drug, to date no detailed polysomnographic study is available on its effect on sleep.
Gabriella Nyitrai, Béla Kiss, Bence Farkas, Ottilia Balázs, Pálma Diószegi, Balázs Lendvai, András Czurkó   +6 more
openaire   +2 more sources

Cariprazin

pharma-kritik, 2019
Ein neues Neuroleptikum, das ungefähr dieselben Wirkungen hat wie Aripiprazol, aber durch eine sehr lange Halbwertszeit auffällt.
openaire   +1 more source

Cariprazine (RGH-188)

Minerva Psichiatrica e Psicologica, 2017
INTRODUCTION: Cariprazine (RGH-188) is a novel antipsychotic drug that exerts partial agonism of dopamine D2/D3 receptors with preferential binding to D3 receptor, antagonism of 5HT2B receptors and partial agonism of 5HT1A. Its interesting pharmacodynamic profile suggests its potential in the treatment of a plethora of psychiatric disorders.
Orsolini, Laura, Iasevoli, Felice, Prinzivalli, Emiliano, Valchera, Alessandro, Fornaro, Michele, Vecchiotti, Roberta, Latiatini, Roberto, Carano, Alessandro, Pompili, Maurizio, Perna, Giampaolo, Vellante, Federica, Mataraataraatarazzo, Ilaria, Martiartinotti, Giovanni, de Bartartolomeis, Andrea, di Giannantonio, Massimo, de Berardis, Domenico   +15 more
openaire   +1 more source

Cariprazine: First Global Approval

Drugs, 2015
Cariprazine (Vraylar) is an oral atypical antipsychotic originated by Gedeon Richter. It is a potent dopamine D3 and D2 receptor partial agonist, which preferentially binds to the D3 receptor. Cariprazine also has partial agonist activity at serotonin 5-HT1A receptors. In September 2015, cariprazine received its first global approval in the USA for the
openaire   +2 more sources

Cariprazine

Reactions Weekly, 2023
  +4 more sources

Brexpiprazole, cariprazine hydrochloride, and flibanserin

Journal of the American Pharmacists Association, 2016
Brexpiprazole (RexultidOtsuka) is an atypical antipsychotic agent with properties and uses that are most similar to those of aripiprazole (e.g., Abilify). It is indicated for the treatment of patients with schizophrenia, and for adjunctive treatment in patients with major depressive disorder (MDD).
Daniel A, Hussar, Rebecca, Shatynski
openaire   +2 more sources